Abstract
Effects of eight small aromatic isothiocyanatosulphonates, of the aliphatic 2-isothiocyanatoethene-1-sulphonate (IES), and of the parent amines were studied on contractions of the rat vas deferens elicited by α,β-methy-lene ATP (α,β-MeATP; mediated by P2X-purinoceptors), relaxations of the carbachol-precontracted guinea-pig taenia coli elicited by adenosine 5′-O-(2-thiodiphosphate) (ADPβS; mediated by P2Y-purinoceptors), and the degradation of ATP by rat vas deferens tissue.
The aromatic isothiocyanato-sulphonates all reduced contractions of the rat vas deferens elicited by α,β-methy-lene ATP. The antagonism was non-competitive, with depression of the maximum of the concentration-response curve of α,β-MeATP and incomplete reversibility. The IC50 values were between 11 and 54 μM. In the guineapig taenia coli, the aromatic compounds shifted the concentration-response curve of ADPβS to the right in a surmountable manner (one exception), and where three concentrations were tested, the Arunlakshana-Schild regression was linear and its slope did not differ from 1. The apparent K d values were between 10 and 214 μM. The removal of ATP from the medium by vas deferens tissue was decreased by the aromatic isothiocyanates with IC25% values between 25 and 464 μM. IES and the parent amines were inactive or almost inactive (parent amines not tested on ATP breakdown).
The results indicate that the isothiocyanato residue as well as the aromatic core are essential for P2-purinoceptor blockade. At the P2X-purinoceptor, potency increases with the size of the molecules but is independent of the position of the isothiocyanato and sulphonate substituents. No simple structure-activity relationship for the P2Y-purinoceptor and the ATP-degrading ecto-nucleotidases can be derived beyond the apparent lack of a major influence of the position of the substituents. 2-Isothiocyanatonaphthalene1-sulphonate (β-INS) seems to be interesting because of relatively high P2X-selectivity versus both the P2Y-purinoceptor and ecto-nucleotidases.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abbracchio MP, Burnstock G (1994) Purinoceptors: are there families of P2X and P2Y purinoceptors? Pharmacol Ther 64:445–475
Arunlakshana O, Schild HO (1959) Some quantitative uses of drug antagonists. Br J Pharmacol 14:48–58
Beukers MW, Kerkhof CJM, van Rhee MA, Ardanuy U, Gurgel C, Widjaja H, Nickel P, Uzerman AP, Soudijn W (1995) Suramin analogs, divalent cations and ATPγS as inhibitors of ecto-ATPase. Naunyn-Schmiedeberg's Arch Pharmacol 351:523–528
Braunitzer G, Schrank B, Ruhfus A, Petersen S, Petersen U (1971) Zur vollständigen Sequenzanalyse von Peptiden mit Quadrol. Hoppe-Seyler's Z Physiol Chem 352:1730–1732
Buell G, Lewis C, Collo G, North RA, Surprenant A (1996) An antagonist-insensitive P2X receptor expressed in epithelia and brain. EMBO J 15:55–62
Bültmann R, Starke K (1994a) Blockade by 4,4′-diisothiocyanatostilbene-2,2′-disulphonate (DIDS) of P2X-purinoceptors in rat vas deferens. Br J Pharmacol 112:690–694
Bültmann R, Starke K (1994b) P2-purinoceptor antagonists discriminate three contraction-mediating receptors for ATP in rat vas deferens. Naunyn-Schmiedeberg's Arch Pharmacol 349:74–80
Bültmann R, Starke K (1995) Reactive red 2: a P2Y-selective purinoceptor antagonist and an inhibitor of ecto-nucleotidase. Naunyn-Schmiedeberg's Arch Pharmacol 352:477–482
Bültmann R, Driessen B, Gonçalves J, Starke K (1995a) Functional consequences of inhibition of nucleotide breakdown in rat vas deferens: a study with Evans blue. Naunyn-Schmiedeberg's Arch Pharmacol 351:555–560
Bültmann R, Pause B, Kurz G, Starke K (1995b) Blockade of P2-purinoceptors by isothiocyanates. Naunyn-Schmiedeberg's Arch Pharmacol 352:R21
Bültmann R, Dudeck O, Starke K (1996a) Evaluation of P2-purinoceptor antagonists at two relaxation-mediating P2-purinoceptors in guinea-pig taenia coli. Naunyn-Schmiedeberg's Arch Pharmacol 353:445–451
Bültmann R, Wittenburg H, Pause B, Kurz G, Nickel P, Starke K (1996b) P2-Purinoceptor antagonists: III. Blockade of P2-purinoceptor subtypes and ecto-nucleotidases by compounds related to suramin. Naunyn-Schmiedeberg's Arch Pharmacol 354:498–504
Burnstock G, Kennedy C (1985) Is there a basis for distinguishing two types of P2-purinoceptor? Gen Pharmacol 16:433–440
Cabantchik ZI, Greger R (1992) Chemical probes for anion transporters of mammalian cell membranes. Am J Physiol 262:C803-C827
Chen CC, Akopian AN, Sivilotti L, Colquhoun D, Burnstock G, Wood JN (1995) A P2X purinoceptor expressed by a subset of sensory neurons. Nature 377:428–431
Driessen B, von Kugelgen I, Starke K (1993) Neural ATP release and its α2-adrenoceptor-mediated modulation in guinea-pig vas deferens. Naunyn-Schmiedeberg's Arch Pharmacol 348:358–366
Driessen B, Reimann W, Selve N, Friderichs E, Bültmann R (1994) Antinociceptive effect of intrathecally administered P2-purinoceptor antagonists in rat. Brain Res 666:182–188
Dudeck O, Bültmann R, Starke K (1995) Two relaxation-mediating P2-purinoceptors in guinea-pig taenia coli. Naunyn-Schmiedeberg's Arch Pharmacol 351:107–110
Dwulet FE, Gurd FRN (1976) A comparison of sulfonated phenylisothiocyanates for reducing losses of lysine-containing peptides during automated sequencing. Anal Biochem 76:530–538
Evans RJ, Lewis C, Buell G, Valera S, North RA, Surprenant A (1995) Pharmacological characterization of heterologously expressed ATP-gated cation channels (P2X-purinoceptors). Mol Pharmacol 48:178–183
Furchgott RF (1972). The classification of adrenoceptors (adrenergic receptors). An evaluation from the standpoint of receptor theory. In: Blaschko H, Muscholl E (eds) Catecholamines. Handbook of experimental pharmacology, vol 33. Springer, Berlin Heidelberg New York, pp 283–335
Ho BT, Huo YY, Newman RA, Levin VA (1992) Analgesic activity of anticancer agent suramin. Anti-Cancer Drugs 3:91–94
Hourani SMO, Chown JA (1989) The effects of some possible inhibitors of ectonucleotidases on the breakdown and pharmacological effects of ATP in the guinea-pig urinary bladder. Gen Pharmacol 20:413–416
Kennedy C, Leff P (1995) How should P2X purinoceptors be classified pharmacologically? Trends Pharmacol Sci 16:168–174
Khakh BS, Michel A, Humphrey PPA (1994) Estimates of antagonist affinities at P2X purinoceptors in rat vas deferens. Eur J Pharmacol 263:301–309
Khakh BS, Surprenant A, Humphrey PPA (1995a) A study on P2X purinoceptors mediating the electrophysiological and contractile effects of purine nucleotides in rat vas deferens. Br J Pharmacol 115:177–185
Khakh BS, Michel AD, Humphrey PPA (1995b) Inhibition of ectoATPase and Ca-ATPase in rat vas deferens by P2 purinoceptor antagonists. Br J Pharmacol 115:2P
Kurz AK, Bültmann R, Driessen B, von Kugelgen I, Starke K (1994) Release of ATP in rat vas deferens: origin and role of calcium. Naunyn-Schmiedeberg's Arch Pharmacol 350:491–498
Lambrecht G, Friebe T, Grimm U, Windscheif U, Bungardt E, Hildebrandt C, Bäumert HG, Spatz-Kümbel G, Mutschler E (1992) PPADS, a novel functionally selective antagonist of P2 purinoceptor-mediated responses. Eur J Pharmacol 217:217–219
McMillian MK, Soltoff SP, Lechleiter JD, Cantley LC, Talamo BR (1988) Extracellular ATP increases free cytosolic calcium in rat parotid acinar cells. Biochem J 255:291–300
Motulsky HJ, Ransnas LA (1987) Fitting curves to data using nonlinear regression: a practical and nonmathematical review. FASEB J 1:365–374
Soltoff SP, McMillian MK, Talamo BR, Cantley LC (1993) Blockade of ATP binding site of P2 purinoceptors in rat parotid acinar cells by isothiocyanate compounds. Biochem Pharmacol 45:1936–1940
Valera S, Hussy N, Evans RJ, Adam N, North RA, Surprenant A, Buell G (1994) A new class of ligand-gated ion channel defined by P2X receptor for extracellular ATP. Nature 371:516–519
Waud DR (1976) Analysis of dose-response relationships. In: Narahashi T, Bianchi CP (eds) Advances in general and cellular pharmacology, vol 1. Plenum, New York London, pp 145–178
Windscheif U, Ralevic V, Bäumert HG, Mutschler E, Lambrecht G, Burnstock G (1994) Vasoconstrictor and vasodilator responses to various agonists in the rat perfused mesenteric arterial bed: selective inhibition by PPADS of contractions mediated via P2X-purinoceptors. Br J Pharmacol 113:1015–1021
Windscheif U, Pfaff O, Ziganshin AU, Hoyle CHV, Bäumert HG, Mutschler E, Burnstock G, Lambrecht G (1995) Inhibitory action of PPADS on relaxant responses to adenine nucleotides or electrical field stimulation in guinea-pig taenia coli and rat duodenum. Br J Pharmacol 115:1509–1517
Wittenburg H, Bültmann R, Pause B, Ganter C, Kurz G, Starke K (1996) P2-Purinoceptor antagonists: II. Blockade of P2-purinocep for subtypes and ecto-nucleotidases by compounds related to Evans blue or trypan blue. Naunyn-Schmiedeberg's Arch Pharmacol 354:491–497
Ziganshin AU, Hoyle CHV, Bo X, Lambrecht G, Mutschler E, Bäumert HG, Burnstock G (1993) PPADS selectively antagonizes P2X-purinoceptor-mediated responses in the rabbit urinary bladder. Br J Pharmacol 110:1491–1495
Ziganshin AU, Ziganshina LE, King BF, Pintor J, Burnstock G (1996) Effects of P2-purinoceptor antagonists on degradation of adenine nucleotides by ecto-nucleotidases in folliculated oocytes of Xenopus laevis. Biochem Pharmacol 51:897–901
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bultmann, R., Pause, B., Wittenburg, H. et al. P2-purinoceptor antagonists: I. Blockade of P2-purinoceptor subtypes and ecto-nucleotidases by small aromatic isothiocyanato-sulphonates. Naunyn-Schmiedeberg's Arch Pharmacol 354, 481–490 (1996). https://doi.org/10.1007/BF00168440
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00168440